What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

被引：18

作者：

Liu, Joyce F. ^{[1
]}

Matulonis, Ursula A. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA

来源：

CURRENT ONCOLOGY REPORTS | 2016年 / 18卷 / 05期

关键词：

Ovarian cancer; PARP inhibitors; Olaparib; Veliparib; Rucaparib; Niraparib; RECURRENT EPITHELIAL OVARIAN; OLAPARIB MAINTENANCE THERAPY; RECOMBINATION DNA-REPAIR; NEGATIVE BREAST-CANCER; HOMOLOGOUS RECOMBINATION; POLY(ADP-RIBOSE) POLYMERASE; FALLOPIAN-TUBE; DOWN-REGULATION; PHASE-II; PRIMARY PERITONEAL;

D O I：

10.1007/s11912-016-0515-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly-ADP-ribose polymerase (PARP) inhibitors have been one of the most exciting developments in the treatment of ovarian cancer in recent years. Demonstration of anticancer activity has led to the European Medicines Agency (EMA) approval of the PARP inhibitor (PARPi) olaparib as maintenance therapy in women with BRCA-mutated (BRCAm) ovarian cancer with platinum-sensitive recurrence following response to platinum therapy and the US Food and Drug Administration (US FDA) approval of olaparib in relapsed germline BRCA-mutated (gBRCAm) ovarian cancer in women who have received at least three prior chemotherapy treatments, both occurring in 2014. Additional trials are underway or awaiting final analysis with olaparib, other PARPis, and PARPi combinations to further elucidate the activity of these drugs in various clinical settings. This review will focus on the current clinical experience and ongoing trials with PARPis in ovarian cancer.

引用

页数：9

共 50 条

[1] What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Joyce F. Liu
Ursula A. Matulonis
[J]. Current Oncology Reports, 2016, 18
[2] PARP Inhibitors in Ovarian Cancer Treatment
Spriggs, David R.
Longo, Dan L.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22): : 2197 - 2198
[3] PARP Inhibitors for the Treatment of Ovarian Cancer
Cortesi, Laura
Toss, Angela
Cucinotto, Iole
[J]. CURRENT CANCER DRUG TARGETS, 2018, 18 (09) : 877 - 893
[4] PARP inhibitors in the treatment of ovarian cancer
Alain G. Zeimet
Verena Wieser
Katharina Knoll
Daniel Reimer
Christian Marth
[J]. memo - Magazine of European Medical Oncology, 2020, 13 : 198 - 201
[5] PARP inhibitors in the treatment of ovarian cancer
Zeimet, Alain G.
Wieser, Verena
Knoll, Katharina
Reimer, Daniel
Marth, Christian
[J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2020, 13 (02) : 198 - 201
[6] PARP inhibitors in the treatment of ovarian cancer: a review
Washington, Christina R.
Moore, Kathleen N.
[J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2021, 33 (01) : 1 - 6
[7] PARP inhibitors for targeted treatment in ovarian cancer
Dizon, Don S.
[J]. LANCET, 2017, 390 (10106): : 1929 - 1930
[8] Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer
Kurnit, Katherine C.
Coleman, Robert L.
Westin, Shannon N.
[J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (12)
[9] Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer
Katherine C. Kurnit
Robert L. Coleman
Shannon N. Westin
[J]. Current Treatment Options in Oncology, 2018, 19
[10] PARP-INHIBITORS ROLE IN THE TREATMENT OF OVARIAN CANCER
Mahon, Lauren
[J]. ONCOLOGY NURSING FORUM, 2023, 50 (02)

← 1 2 3 4 5 →